Kymera Therapeutics (KYMR) Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Accumulated Expenses data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 70.92% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 70.92% decrease from a year earlier, with the FY2025 full-year figure at $42.3 million, up 21.24% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.7 million, down from $42.3 million in the prior quarter.
• Over the last five years, Accumulated Expenses for KYMR reached as high as $42.3 million in Q4 2025 and fell as low as $3.6 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $19.2 million across 5 years, with a median of $22.5 million in 2023.
• Across the five-year window, Accumulated Expenses surged 1538.56% in 2022 and sank 82.71% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $27.5 million in 2022, then grew by 23.13% to $33.9 million in 2023, then gained by 2.96% to $34.9 million in 2024, then advanced by 21.24% to $42.3 million in 2025, then plunged by 84.1% to $6.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $6.7 million in Q1 2026, $42.3 million in Q4 2025, and $11.7 million in Q3 2025.